Federal contract award
75N91022F00001
VRC HIV MAB-RESEARCH, DEVELOPMENT, AND PRODUCTION TO SUPPORT HIV MONOCLONAL ANTIBODY DEVELOPMENT - THE PRIMARY OBJECTIVE IS TO SUPPORT CELL LINE DEVELOPMENT, PROCESS DEVELOPMENT, ANALYTICAL DEVELOPMENT, REAGENT PRODUCTION, MANUFACTURING, AND TESTING
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | NIH NCI |
| NAICS | 541715 — Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
| PSC | AN12 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH |
| Parent award / vehicle | 75N91019D00024 |
| Set-aside | Not reported |
| Pricing type | COST PLUS FIXED FEE |
| Obligations | $19.1M |
| Current contract value | $19.1M |
| Potential contract value / ceiling | $19.4M |
| Start date | Feb 1, 2022 |
| Current end date | Sep 15, 2027 |
| Potential end date | Sep 15, 2027 |
| Latest award activity | Feb 13, 2024 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 4 of 4 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Feb 13, 2024 | P00003 | $0 | VRC HIV MAB-RESEARCH, DEVELOPMENT, AND PRODUCTION TO SUPPORT HIV MONOCLONAL ANTIBODY DEVELOPMENT - THE PRIMARY OBJECTIVE IS TO SUPPORT CELL LINE DEVELOPMENT, PROCESS DEVELOPMENT, ANALYTICAL DEVELOPMENT, REAGENT PRODUCTION, MANUFACTURING, AND TESTING |
| Sep 12, 2022 | P00002 | $8.1M | VRC HIV MAB-RESEARCH, DEVELOPMENT, AND PRODUCTION TO SUPPORT HIV MONOCLONAL ANTIBODY DEVELOPMENT - THE PRIMARY OBJECTIVE IS TO SUPPORT CELL LINE DEVELOPMENT, PROCESS DEVELOPMENT, ANALYTICAL DEVELOPMENT, REAGENT PRODUCTION, MANUFACTURING, AND TESTING |
| Aug 15, 2022 | P00001 | $6.3M | VRC HIV MAB-RESEARCH, DEVELOPMENT, AND PRODUCTION TO SUPPORT HIV MONOCLONAL ANTIBODY DEVELOPMENT - THE PRIMARY OBJECTIVE IS TO SUPPORT CELL LINE DEVELOPMENT, PROCESS DEVELOPMENT, ANALYTICAL DEVELOPMENT, REAGENT PRODUCTION, MANUFACTURING, AND TESTING |
| Feb 1, 2022 | 0 | $4.7M | VRC HIV MAB-RESEARCH, DEVELOPMENT, AND PRODUCTION TO SUPPORT HIV MONOCLONAL ANTIBODY DEVELOPMENT - THE PRIMARY OBJECTIVE IS TO SUPPORT CELL LINE DEVELOPMENT, PROCESS DEVELOPMENT, ANALYTICAL DEVELOPMENT, REAGENT PRODUCTION, MANUFACTURING, AND TESTING |
Estimated positioning window
Nov 1, 2026 – Mar 15, 2027
80/100
Why this recompete signal
Contract timing and recorded acquisition signals at the time of calculation.
Stored score: 80/100. Available recorded signals: 75 points.
- Contract end 2027-09-15 (318 days from calculation)
- +35 points
- 240 historical awards in this buyer and category group
- +15 points
- 4 recorded award transactions
- +10 points
- Latest award action: 2024-02-13
- +0 points
- Parent award identifier recorded
- +5 points
- Solicitation identifier recorded
- +10 points
- Linked official forecast
- +0 points
- Calculated on
- 2026-11-01 10:17:53.997580+00:00
The historical group combines buyer, NAICS, and PSC. Multiple awards in this group do not by themselves establish repeated competitions.
Rule-based research score; it does not measure your chance of winning.
This older calculation does not retain a complete reproducible breakdown. Missing or changed inputs are not assigned invented points: Original award-value bonus input.
Recompete score calculated Nov 1, 2026.
Research next steps
- Check the linked forecast or SAM for a confirmed solicitation and current timing.
- Confirm the ordering vehicle and your eligibility or a qualified teaming route.
- Review the award scope and buyer evidence before making a bid/no-bid decision.